Clinical trials: Platelet Reactivity
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Peripheral Artery Disease, Critical Limb Ischemia
Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty
Dual antiplatelet therapy has a key role in a prevention of thrombosis of treated artery in patients undergoing percutaneous transluminal angioplasty (PTA).
- Conditions
- Peripheral Artery Disease, Critical Limb Ischemia, Claudication, Intermittent
- Trial name
- PAD (NCT04165629)
- Testing
- Aspirin 300mg and Clopidogrel 300mg
- Where
- Serbia
- Volunteers
- 450 people
- Sponsor
- Clinical Centre of Serbia
Critical Illness
High "on Treatment" Platelet Reactivity in the Intensive Care Unit
High "on treatment" platelet reactivity is defined as a poor pharmacodynamic response to the administration of acetylsalicylic acid or clopidogrel.
- Trial name
- NCT02285751
- Testing
- acetylsalicylic acid, clopidogrel, prasugrel
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
Clopidogrel and Prasugrel are pro-drug necessitating conversion in active metabolites through CYP 450 system (CYP), particularly CYP3A and CYP2C19 isoforms.
- Trial name
- dOPPLER (NCT02028234)
- Testing
- Pantoprazole,, Omeprazole
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Roma La Sapienza
Coronary Artery Disease
Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity
Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events.
- Trial name
- PEARL (NCT01567774)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Stroke
Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research
The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform.
- Trial name
- NCT02618265
- Testing
- Mobile terminal, traditional management, website platform management
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University Third Hospital
Acute Coronary Syndrome, Antiplatelet Therapy
Platelet Reactivity And Clinical ThrombotIC Events Study
Platelet function testing has been considered for DAPT strategy adjustments to reduce the patient's risk of ischemia and bleeding.
- Conditions
- Acute Coronary Syndrome, Antiplatelet Therapy, Platelet Reactivity
- Trial name
- PRACTICE (NCT03525145)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shenyang Northern Hospital
COPD Exacerbation
Platelet Activation and Reactivity in Acute Exacerbations of COPD
Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of…
- Trial name
- NCT03017625
- Testing
- Blood is drawn
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Myocardial Infarction, STEMI
Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
Acute myocardial infarction is generally caused by a thrombotic occlusion of coronary arteries. Primary aim of early therapy is a fast and complete reperfusion of the infarcted myocardium.
- Trial name
- ETAMI (NCT01327534)
- Testing
- Prasugrel, Clopidogrel
- Where
- 3 sites in France, Germany
- Volunteers
- 63 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung
Acute Coronary Syndromes
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
The investigators hypothesize that reduced loading dose of prasugrel followed by reduced maintenance dose of prasugrel in acute coronary syndrome patients with CYP2C19 polymorphism undergoing percutaneous coronary intervention…
- Trial name
- PRAISE-GENE (NCT01641510)
- Testing
- Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Dong-A University
Carotid Artery Disease
Residual Platelet Reactivity in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting
A carotid stenosis is treated with invasive procedures of revascularization when the lumen is reduced by more than 70% or when the lumen is reduced by more than 50% in patients who have had symptoms attributable to the affected…
- Trial name
- ARS (NCT01449617)
- Testing
- Aspirin plus clopidogrel
- Where
- Italy
- Volunteers
- 272 people
- Sponsor
- Azienda Ospedaliera di Perugia
Platelet Aggregation
Low Dose Aspirin Studied With the AggreGuide
This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.
- Trial name
- NCT01603966
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Edward R. Teitel, M.D.
Erythropoietin Adverse Reaction
The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2.
- Trial name
- EPOASA (NCT04330729)
- Testing
- Acetylsalicylic acid
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Zealand University Hospital
Coronary Artery Disease, Platelet Reactivity
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
Extreme body weights (BW) or body mass index (BMI) affect the pharmacokinetics of antithrombotic drugs and consequently may affect cardiovascular risk during treatment.
- Trial name
- BW-ACCORD (NCT05657041)
- Testing
- Clopidogrel
- Where
- 2 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- St. Antonius Hospital
Acute Coronary Syndrome
Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
High platelet reactivity unit (PRU) after loading dose clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is related to high risk of short and long term recurrent ischemic events including stent…
- Trial name
- PRAISE-HPR (NCT01609647)
- Testing
- Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Dong-A University
Acute ST-elevation Myocardial Infarction
On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction
Adequate platelet inhibition with dual antiplatelet therapy is a key therapeutic goal after primary percutaneous coronary intervention (PPCI), aimed at protecting against stent thrombosis and increased mortality.
- Trial name
- PLATFORM (NCT01739556)
- Testing
- Antiplatelet Regimen Modification (aspirin or ticagrelor)
- Where
- Serbia
- Volunteers
- 242 people
- Sponsor
- Clinical Centre of Serbia
Unruptured Intracranial Aneurysm, Stents
Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms
This study was designed to identify high platelet reactivity (HPR) who might have in-stent thrombosis in unruptured aneurysm with intracranial stent placement with light transmittance platelet aggregometry (LTA).
- Conditions
- Unruptured Intracranial Aneurysm, Stents, Antiplatelet Drugs
- Trial name
- APISIA Trail (NCT03989557)
- Testing
- Aspirin and clopidogrel/Ticagrelor, Light transmittance aggregometry
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Beijing Neurosurgical Institute
Myocardial Infarction
Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)
This is a single-center, randomized, single-blind, investigator-initiated, pharmacological study with a parallel design. Patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention and…
- Trial name
- PRO-GR-4 (NCT01338909)
- Testing
- Prasugrel, Clopidogrel
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- University of Patras
Acute Coronary Syndrome, Platelet Function and Reactivity Tests
Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy
Thus far, no study has evaluated the impact on aspirin in addition to the newer and more potent P2Y12 inhibitors, among ACS patients and current guidelines recommend dual anti-platelet therapy consisting of aspirin and a novel…
- Conditions
- Acute Coronary Syndrome, Platelet Function and Reactivity Tests, Novel P2Y12 Inhibitors
- Trial name
- NCT02049762
- Testing
- Aspirin
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Sheba Medical Center